"We are excited to partner with Atomwise, given their leadership in the field of virtual screening and AI-based molecular design. Together, we aim at making the drug ... Co, Eli Lilly, and AbbVie.

Genesis was set up around a physics-based AI platform – called Genesis Exploration of Molecular Space (GEMS) – that applies generative and predictive AI technology to the design and generation ...

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

On Saturday, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) said adolescent patients with severe alopecia areata (AA) treated with once-daily oral baricitinib 4 mg and 2 mg saw ...

(Reuters) - Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and Mexico in the second half of 2025 as production capacity ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico in 2025, Chief Financial Officer Lucas Montarce said on Monday.

Let's find out. So, first let's talk about the Eli Lilly story so far. It's important to remember that Lilly isn't only a weight loss drug company; it also sells a wide variety of products across ...

Discouraging news from a rival dampened sentiment on the pharmaceutical giant's shares. This concerned a next-generation weight loss drug. That negative investor reaction was directed at companies ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...